< Back to all news

Oslo District Court Rules for Amgen

AmCham

Category: Pharmaceutical

The Oslo District Court concluded last Friday that the Norwegian Medicines Agency’s recent inclusion of Neupogen / filgrastim on the substitution list is invalid. The Norwegian Pharmacy Act, therefore, does not authorize substitution of these biological medicines.

Source: LMI


Published: 06.04.2011


Read more...
1 2 3 644

News Archive